KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bionano Genomics (BNGO) Receivables - Other (2021 - 2025)

Bionano Genomics recorded quarterly Receivables - Other of $200000.0 in Q4 2025, down 33.33% quarter-over-quarter from $300000.0 in Q4 2024, and down 33.33% year-over-year from $300000.0 in Q4 2024.

Bionano Genomics' Receivables - Other history runs 5 years deep, the most recent figure standing at $200000.0 for Q4 2025.

  • In Q4 2025, Receivables - Other fell 33.33% year-over-year to $200000.0; the TTM figure through Dec 2025 stood at $200000.0 (down 33.33% YoY), while the FY2025 annual figure was $200000.0, down 33.33% from the prior year.
  • Receivables - Other came in at $200000.0 for Q4 2025 at Bionano Genomics, down from $300000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $474000.0 in Q4 2022 to a low of $200000.0 in Q4 2025.
  • A 5-year average of $340600.0 and a median of $342000.0 in 2023 frame the typical range for Receivables - Other.
  • Across the five-year window, Receivables - Other advanced 22.48% in 2022 and tumbled 33.33% in 2025, its largest moves.
  • Bionano Genomics' Receivables - Other stood at $387000.0 in 2021, then climbed by 22.48% to $474000.0 in 2022, then fell by 27.85% to $342000.0 in 2023, then dropped by 12.28% to $300000.0 in 2024, then tumbled by 33.33% to $200000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods registered $200000.0, $300000.0, and $342000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Bionano Genomics 14.92 Mn 539,417.67 3.25 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 200,000.00
Dec 31, 2025 200,000.00
Dec 31, 2024 300,000.00
Dec 31, 2024 300,000.00
Dec 31, 2023 342,000.00
Dec 31, 2023 342,000.00
Dec 31, 2022 474,000.00
Dec 31, 2022 474,000.00
Dec 31, 2021 387,000.00
Dec 31, 2021 387,000.00